{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+tacrolimus&page=4", "query": { "intervention": "Standard tacrolimus", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 208, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+tacrolimus&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+tacrolimus&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:35:32.512Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02588339", "title": "Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "GVHD" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2016-03-04", "completion_date": "2021-07-13", "has_results": true, "last_update_posted_date": "2021-07-21", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588339" }, { "nct_id": "NCT07352566", "title": "Utilization of a Microdevice for Psoriasis and Atopic Dermatitis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Atopic Dermatitis" ], "interventions": [ { "name": "In situ cutaneous microdevice", "type": "DEVICE" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Calcipotriene", "type": "DRUG" }, { "name": "Tapinarof", "type": "DRUG" }, { "name": "Crisaborole", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Baractinib", "type": "DRUG" }, { "name": "Abrocitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Nemolizumab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Roflumilast", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-08-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07352566" }, { "nct_id": "NCT05316701", "title": "Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoid Leukemia", "Mixed Phenotype Acute Leukemia", "Undifferentiated Leukemia", "Myelodysplastic Syndrome", "Acute Leukemia", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Orca-T", "type": "BIOLOGICAL" }, { "name": "Standard-of-Care", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Orca Biosystems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 187, "start_date": "2022-06-21", "completion_date": "2026-07", "has_results": true, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05316701" }, { "nct_id": "NCT02294032", "title": "The Role of B Cells in Kidney Allograft Dysfunction", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Kidney; Complications, Allograft", "Transplantation Infection" ], "interventions": [ { "name": "Immunosuppressive Agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "2 Years to 85 Years" }, "enrollment_count": 180, "start_date": "2014-08-28", "completion_date": "2023-04-24", "has_results": false, "last_update_posted_date": "2023-05-19", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294032" }, { "nct_id": "NCT02145403", "title": "Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancies", "Relapse", "Graft-Versus-Host Disease" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 53, "start_date": "2014-10", "completion_date": "2020-10-16", "has_results": true, "last_update_posted_date": "2022-01-03", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02145403" }, { "nct_id": "NCT06962800", "title": "A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Membranous Nephropathy" ], "interventions": [ { "name": "Felzartamab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Standard of Care IST", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 180, "start_date": "2025-05-22", "completion_date": "2031-01-17", "has_results": false, "last_update_posted_date": "2026-11-09", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 16, "location_summary": "Huntsville, Alabama • Fresno, California • Los Angeles, California + 12 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06962800" }, { "nct_id": "NCT05736419", "title": "A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease", "Thalassemia, Beta", "Thalassemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Rabbit ATG", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "2 Years to 50 Years" }, "enrollment_count": 24, "start_date": "2023-02-09", "completion_date": "2027-02-09", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05736419" }, { "nct_id": "NCT00928811", "title": "Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "End Stage Renal Disease" ], "interventions": [ { "name": "basiliximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Drexel University College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 5, "start_date": "2009-05", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2015-02-10", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00928811" }, { "nct_id": "NCT02766465", "title": "Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "r-ATG", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplant", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Standard of Care", "type": "PROCEDURE" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 138, "start_date": "2017-03-16", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 35, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02766465" }, { "nct_id": "NCT03656926", "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiolitis Obliterans", "Chronic Rejection of Lung Transplant", "Lung Transplant Rejection", "Lung Transplant; Complications", "Lung Transplant Failure and Rejection", "Chronic Lung Allograft Dysfunction" ], "interventions": [ { "name": "Liposomal Cyclosporine A", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zambon SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2019-03-26", "completion_date": "2024-03-12", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-11-15T12:35:32.512Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656926" } ] }